The Lymphoma Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
LLM 2021 | Antibody-drug conjugates and checkpoint inhibitors in Hodgkin lymphoma
Jonathan Friedberg, MD MMSc, Wilmot Cancer Center, University of Rochester, Rochester, NY, comments on antibody-drug conjugates and checkpoint inhibitors in the treatment of relapsed Hodgkin lymphoma, whose efficacy supports their use early in the disease, including after the first relapse or as part of upfront therapy. Looking into the future, interesting preliminary results suggest both drug types could be used in combination, for which confirmatory trials are planned. This interview took place at the Lymphoma, Leukemia & Myeloma Congress 2021.
